Our findings that RTVP-1 was preferentially expressed in the mesenchymal subtype of GBM and predicted poor clinical outcome and the fact the promoter of RTVP-1 contains binding sites for STAT3 and C/EBPβ led us to examine the involvement of this protein in the regulation of the mesenchymal phenotype of GBM. This evidence concerns the gene GLIPR1 and glioblastoma.